摘要
目的观察依达拉奉治疗外伤性蛛网膜下腔出血(tSAH)的临床效果。方法将90例tSAH患者随机分为依达拉奉组和常规治疗组,两组均采用相同的脑脊液置换、尼莫地平治疗和对症处理;依达拉奉组加用依达拉奉30mg2次/日,静脉滴注,连用14d,观察两组疗效。结果在头痛症状减轻程度及持续时间、脑膜刺激征持续时间、降低颅内压等方面,治疗组明显优于对照组(P<0.05)。结论依达拉奉用于治疗外伤性蛛网膜下腔出血安全有效。
Objective To evaluate the efficacy of edaravone in treatment of traumatic subarachnoid hemorrhage （tSAH）. Methods Ninety patients with tSAH were randomly divided into treatment group（n=45） and control group（n=45）. All the patients were given the same treatment except for the dose of edaravone, 30 mg once,twice a day for 14 days in treatment group. The evaluation of therapeutic effects were observed in both groups. Results The therapeutic effect of treatment group was better than the control group in terms of reducing headache, decreasing mening stimulationsign, and reducing intracranial pressure（P〈 0.05）. Conclusion Edaravone, as a new hydroxy free radical scavenger, can be used to treat Traumatic subarachnoid hemorrhage. The therapy is elective.
出处
《中国现代医生》
2009年第12期92-93,共2页
China Modern Doctor
